Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year
- Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution
- Recognition highlights proactive alignment with evolving expectations from global stakeholders
Incheon, S. Korea, April 27, 2026 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has been included in the Dow Jones Best-in-Class World Index (formerly the Dow Jones Sustainability Index) for the fifth consecutive year, reaffirming the company’s continued commitment to sustainable growth and responsible business practices.
The annual index review is based on S&P Global Corporate Sustainability Assessment (CSA), a globally recognized benchmark that evaluates over 2,500 companies across a broad range of environmental, social, and governance (ESG) criteria, including risk management and operational performance. Companies ranked within the top tier of their respective industries are selected for index inclusion.
Samsung Biologics was recognized for its dedication to improving its overall performance through enhanced sustainability data disclosures and the continued advancement of ESG management practices. The company delivered strong results across key areas, including supply chain management, environmental stewardship, and workplace health and safety. These outcomes demonstrate the company’s ability to embed ESG considerations across its operations and business practices.
“This recognition acknowledges our steady progress in strengthening the sustainability management framework across all areas of the business,” said John Rim, President and CEO of Samsung Biologics, who also serves as a champion of the Sustainable Markets Initiative (SMI) Supply Chains Working Group. “We remain committed to responsible growth, transparent operations, and long-term value creation for clients, communities, and stakeholders.”
The continued inclusion also underscores Samsung Biologics’ proactive response to evolving expectations from global investors and stakeholders, while providing objective recognition of the company’s sustainability performance. Samsung Biologics continues to advance its ESG initiatives through disciplined execution, responsible operations, and transparent governance. This year, the company received an EcoVadis Platinum rating and also won a sustainability award at the CDMO Leadership Awards.
- Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution
- Recognition highlights proactive alignment with evolving expectations from global stakeholders
Incheon, S. Korea, April 27, 2026 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has been included in the Dow Jones Best-in-Class World Index (formerly the Dow Jones Sustainability Index) for the fifth consecutive year, reaffirming the company’s continued commitment to sustainable growth and responsible business practices.
The annual index review is based on S&P Global Corporate Sustainability Assessment (CSA), a globally recognized benchmark that evaluates over 2,500 companies across a broad range of environmental, social, and governance (ESG) criteria, including risk management and operational performance. Companies ranked within the top tier of their respective industries are selected for index inclusion.
Samsung Biologics was recognized for its dedication to improving its overall performance through enhanced sustainability data disclosures and the continued advancement of ESG management practices. The company delivered strong results across key areas, including supply chain management, environmental stewardship, and workplace health and safety. These outcomes demonstrate the company’s ability to embed ESG considerations across its operations and business practices.
“This recognition acknowledges our steady progress in strengthening the sustainability management framework across all areas of the business,” said John Rim, President and CEO of Samsung Biologics, who also serves as a champion of the Sustainable Markets Initiative (SMI) Supply Chains Working Group. “We remain committed to responsible growth, transparent operations, and long-term value creation for clients, communities, and stakeholders.”
The continued inclusion also underscores Samsung Biologics’ proactive response to evolving expectations from global investors and stakeholders, while providing objective recognition of the company’s sustainability performance. Samsung Biologics continues to advance its ESG initiatives through disciplined execution, responsible operations, and transparent governance. This year, the company received an EcoVadis Platinum rating and also won a sustainability award at the CDMO Leadership Awards.
Share article
Related Content